Cellumed, a company specializing in the manufacturing of bio-medical devices, announced on November 12 that it participated in the 'PRS KOREA 2025' conference held at the Grand InterContinental Seoul Parnas in Samseong-dong, Seoul, from November 9 to 11, where it showcased its advanced skin graft technologies.
PRS KOREA is a flagship event organized by the Korean Society of Plastic and Reconstructive Surgeons to enhance the international academic standing of plastic surgery in Korea. This year, the 83rd Annual Meeting of the Korean Society of Plastic and Reconstructive Surgeons and the 28th Annual Meeting of the Korean Cleft Palate-Craniofacial Association were held together, facilitating broad research and active exchange across all fields of reconstructive and aesthetic plastic surgery.
At this conference, Cellumed exhibited three products from its acellular dermal matrix (ADM)-based skin graft product line, the 'CELLUDERM' series: CELLUDERM HD IMPLANT, CELLUDERM FILL, and CELLUDERM ULTRA. All of these products are known for their excellent biocompatibility and low infection rates, making them widely used in various clinical fields such as plastic surgery, breast surgery, orthopedics, and urology.
In particular, the recently launched 'CELLUDERM FILL' attracted significant attention from medical professionals. This new product is an injectable formulation that combines ADM in fine powder form with purified water, optimized for reconstructive procedures such as breast reconstruction surgery.
During the event, Cellumed's booth continuously attracted visits from medical professionals. Through meetings, the company emphasized that the applications of acellular dermal matrix are expanding beyond breast reconstruction to include urology, dermatological aesthetics, and burn treatment. At the same time, Cellumed highlighted the biocompatibility and safety of its products, focusing on enhancing brand credibility and expanding its medical network.
A Cellumed representative stated, "We plan to continue actively participating in major academic conferences both domestically and internationally to promote the technological excellence and clinical competitiveness of the CELLUDERM series. By implementing an aggressive sales and marketing strategy based on differentiated quality, we aim to secure a competitive edge and achieve meaningful market share in the skin graft market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
